Abstract
Management of patients with infectious and inflammatory diseases of the upper respiratory tract is one of the most pressing problems of modern medicine, which is associated with the widespread prevalence of this pathology. The main causative agents of acute respiratory infections (ARI) are viruses, but the frequency of unjustified prescription of antibiotic therapy remains high. Despite significant advances in healthcare, questions of the effectiveness and safety of treatment of patients with ARI and the prevention of complications remain largely open to the present day. In this aspect, the possibility of using the original domestic antiviral drug of plant origin Panavir® in respiratory medicine is of particular interest to doctors and patients. The action of Panavir® is aimed at increasing the body’s resistance to the effects of pathogens and the production of interferons - protective proteins produced by the body in response to pathogen invasion. Panavir® is a biologically active polysaccharide obtained from the plant Solanum tuberosum (tuberous nightshade). This substance has a long-term protective effect, prevents the development of inflammation, and accelerates the restoration of the mucous membrane.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
